Pacira BioSciences Defends Board Nominees Amid Proxy Fight with DOMA
Event summary
- Pacira BioSciences mailed a letter to stockholders on May 27, 2026, urging them to vote for its board nominees ahead of the June 9, 2026, annual meeting.
- The company highlighted a 31% stock increase since launching its 5x30 strategy, with record revenues of $726.4 million and GAAP net income of $7.0 million in 2025.
- Pacira defended its intellectual property strategy, citing a favorable EXPAREL settlement in 2025 that extends exclusivity into 2030.
- The board engaged with 11 stockholders, representing 56.7% of shares outstanding, to address concerns and demonstrate responsiveness.
The big picture
Pacira BioSciences is defending its board nominees and strategic direction amid a proxy fight with DOMA Perpetual, highlighting strong financial performance and pipeline advancements. The company's 5x30 strategy aims to diversify its product portfolio and expand commercial reach, positioning it for long-term growth in the non-opioid pain therapy market. The outcome of the proxy contest and the execution of its strategic initiatives will be critical to sustaining momentum.
What we're watching
- Proxy Fight Outcome
- Whether DOMA Perpetual's challenge to Pacira's board nominees will succeed, potentially altering the company's strategic direction.
- Execution Risk
- The pace at which Pacira can deliver on its 5x30 strategy, including pipeline advancements and commercial expansions.
- Market Positioning
- How Pacira's intellectual property strategy and EXPAREL settlement will impact its competitive advantage in the non-opioid pain therapy market.
Related topics